# DESCRIPTION

## GOVERNMENT FUNDING

- disclose government funding

## BACKGROUND OF THE INVENTION

- describe limitations of homologous recombination

## SUMMARY OF THE INVENTION

- introduce fusion protein
- describe guide nucleotide sequence-programmable DNA binding protein domain
- describe recombinase catalytic domain
- describe optional linker
- describe nuclear localization signal domain
- describe affinity tags
- describe structure of fusion protein
- describe sequence identity of fusion protein
- describe dimer of fusion protein
- describe tetramer of fusion protein

## DEFINITIONS

- define singular and plural forms
- introduce RNA-programmable DNA-binding proteins
- describe Cas9 nuclease and its variants
- explain CRISPR-Cas system and PAM motif
- discuss Cas9 orthologs and sequences
- introduce nuclease-inactivated Cas9 protein (dCas9)
- describe methods for generating Cas9 protein with inactive DNA cleavage domain
- discuss Cas9 variants and their properties
- define Cpf1 variants
- describe NgAgo protein
- introduce PAMless Cas9 variants
- define Cas9 proteins
- explain conjugation and consensus sequence
- define engineered and effective amount
- define linker
- define mutation
- define nuclease and related terms
- define nucleic acid and related terms
- define pharmaceutical composition
- define proliferative disease
- define protein and related terms
- define RNA-programmable nuclease and related terms
- define recombinase and related terms
- provide examples and references
- define recombinases
- motivate applications of recombinases
- describe recombinase structure and function
- introduce recombinant proteins and nucleic acids
- define key terms
- define target site
- define TALE
- define TALEN
- define treatment
- define vector
- define zinc finger
- define zinc finger nuclease
- describe zinc finger nuclease design

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

- introduce embodiments

### Guide Nucleotide Sequence-Programmable DNA Binding Protein

- define programmable DNA binding protein domain
- describe guide nucleotide sequence-programmable DNA binding protein variants
- discuss Cas9 domain mutations and PAM specificity
- introduce other RNA-programmable DNA binding proteins (e.g., Cpf1, Argonaute)
- summarize PAM sequences recognized by guide nucleotide sequence-programmable DNA binding proteins
- introduce guide nucleotide sequence-programmable DNA binding protein
- describe Cpf1 protein
- describe C2c1, C2c2, and C2c3 proteins
- describe Argonaute protein from Natronobacterium gregoryi
- describe Cas9 variants with relaxed PAM requirements
- define linker
- describe linker lengths and flexibilities
- provide examples of linker sequences

### Recombinase Catalytic Domain

- introduce recombinase catalytic domain
- describe suitable recombinases
- discuss mutations in recombinase catalytic domain
- introduce evolved recombinase
- describe altered target sequence preferences
- discuss catalytic domains from evolved recombinases
- describe use of portions of recombinase
- discuss truncation of Cre recombinase
- provide examples of evolved recombinases

### Structure of the Fusion Protein

- define fusion protein structure
- list exemplary fusion protein structures
- describe recombinase catalytic domain variations
- describe guide nucleotide sequence-programmable DNA binding protein domain variations
- describe NLS domain variations
- describe affinity tag variations
- summarize fusion protein structure embodiments
- describe fusion protein structure
- provide alternative embodiments
- list affinity tags
- describe third linker
- specify sequence identity
- explain LSR structure

## EXAMPLES

### Example 1: A Programmable Cas9-Serine Recombinase Fusion Protein that Operates on DNA Sequences in Mammalian Cells

- describe oligonucleotides and PCR
- construct reporters using Golden Gate assembly
- describe plasmid construction and purification
- describe cell culture and transfection
- perform flow cytometry
- identify genomic target sites using Bioconductor
- extract and sequence episomal DNA
- analyze recCas9 catalyzed genomic deletions
- quantify genomic deletion using nested PCR
- introduce programmable Cas9-Serine recombinase fusion protein
- describe fusion of Gin Recombinase to dCas9
- assay recCas9 fusions
- target DNA sequences found in human genome with recCas9
- determine orthogonality of recCas9
- test recCas9 activity on multiple target sites
- demonstrate orthogonal recombination activity
- characterize recCas9 products
- test mutagenesis from recCas9 treatment
- establish recCas9-mediated genomic deletion
- demonstrate recCas9 deletion in human cells
- use alternative recombinases
- test Cre recombinase evolved to target Rosa locus

## EQUIVALENTS AND SCOPE

- description of equivalents and scope of the invention
- explanation of claim language and variations

